首站-论文投稿智能助手
典型文献
Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂)on dose reductions and discontinuation of pyridostigmine bromide tablets,prednisone,and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis
文献摘要:
OBJECTIVE:To investigate the clinical efficacy of Fufang Huangqi decoction(复方黄杞汤剂)in combination with pyridostigmine bromide tablets,prednisone,and tacrolimus in the treatment of type Ⅰ and Ⅱ myasthenia gravis(MG)through changes in the clinical symptom scores of 100 patients with type Ⅰ and Ⅱ MG.This study also aimed to examine dose reductions and dis-continuation of these 3 Western medicines after administration of Fufang Huangqi decoction.METHODS:The clinical data on 100 patients with type Ⅰor Ⅱ MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,China,between June 2017 and June 2020 were collected.The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets,prednisone,and/or tacrolimus at the time of their hospital visit:the Fufang Huangqi decoction group(group A),the pyridostigmine bromide tablets+Fufang Huangqi decoction group(group B),the pyridostigmine bromide tablets+prednisone+Fufang Huangqi decoction group(group C),and the pyridostigmine bromide tablets+tacrolimus+Fufang Huangqi decoction group(group D).The average treatment time was(15.6±11.5)months(range:0.5-55 months).Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed.RESULTS:An overall effectiveness rate of 86.00%was achieved in the 100 patients after treatment for(15.6±11.5)months(range 0.5-55 months).The effectiveness rates were 85.71%in group A,88.24%in group B,76.92%in group C,and 80.00%in group D.The dosage of pyridostigmine bromide was reduced for 69.12%of the patients in group B for the first time after(4.2±4.1)months,and 45.59%of the patients in group B discontinued pyridostigmine bromide after(8.8±6.1)months.The dosage of pyridostigmine bromide was reduced for 46.15%of the patients in group C for the first time after(5.3±3.4)months,and 23.08%of the patients in group C discontinued pyridostigmine bromide after(19.8±11.0)months;76.92%reduced hormone dosage after(2.8±1.9)months,and 23.08%discontinued hormone treatment after(6.7±2.9)months.The dosage of pyridostigmine bromide was reduced for 1 patient in group D after 1 month;this patient discontinued pyridostigmine bromide after 3 months and reduced tacrolimus dosage after 5 months.One patient in group D discontinued pyridostigmine bromide and tacrolimus on his own initiative at 0.5 months and took Fufang Huangqi decoction for 2 months without discontinuing Western medicine.CONCLUSION:Fufang Huangqi decoction is effective for the treatment of type Ⅰ and Ⅱ MG and improves the associated clinical symptoms.Moreover,this agent is conducive to dose reductions and discontinuation of basic Western medicines,thereby reducing the side effects experienced by patients.
文献关键词:
作者姓名:
SHAN Caifeng;ZHANG Jingsheng;LIN Yi;HUANG Xueshi;WANG Zhanyou;PAN Haiou;QIAO Wenjun
作者机构:
the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Liaoning Provincial Key Laboratory for Diagnosis and Treatment of Myasthenia Gravis,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China;Department of General Surgery,the First People's Hospital of Shenyang,Shenyang 110091,China;Institute of Microbial Pharmaceuticals,College of Life and Health Sciences,Northeastern University,Shenyang 110819,China;Institute of Health Sciences,Key Laboratory of Medical Cell Biology of Ministry of Education,China Medical University,Shenyang 110122,China;Liaoning University of Traditional Chinese Medicine,foreign language college,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China
引用格式:
[1]SHAN Caifeng;ZHANG Jingsheng;LIN Yi;HUANG Xueshi;WANG Zhanyou;PAN Haiou;QIAO Wenjun-.Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂)on dose reductions and discontinuation of pyridostigmine bromide tablets,prednisone,and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis)[J].中医杂志(英文版),2022(05):810-817
A类:
pyridostigmine,tablets+Fufang,tablets+prednisone+Fufang,tablets+tacrolimus+Fufang,discontinuing
B类:
Effect,treatment,Huangqi,decoction,黄杞,汤剂,dose,reductions,discontinuation,bromide,patients,type,myasthenia,gravis,OBJECTIVE,To,investigate,clinical,efficacy,combination,MG,through,changes,scores,This,study,also,aimed,examine,these,medicines,after,administration,METHODS,data,who,were,treated,outpatient,department,Affiliated,Hospital,Liaoning,University,Traditional,Chinese,Medicine,China,between,June,collected,divided,into,groups,whether,they,had,taken,their,hospital,visit,average,was,months,range,Changes,medication,analyzed,RESULTS,An,overall,effectiveness,achieved,rates,dosage,reduced,first,discontinued,hormone,this,One,own,initiative,took,without,CONCLUSION,improves,associated,symptoms,Moreover,agent,conducive,basic,thereby,reducing,side,effects,experienced
AB值:
0.26586
相似文献
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu;Ting Li;Zhichao Liao;Hui Yu;Yongtian Zhao;Haixiao Wu;Zhiwu Ren;Jun Zhao;Ruwei Xing;Sheng Teng;Yun Yang;Xiangchun Li;Kexin Chen;Jonathan Trent;Jilong Yang-Department of Bone and Soft Tissue Tumor,2Department of Infection Management,3Key Laboratory of Molecular Cancer Epidemiology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;YuceBio Technology Co.,Ltd.,Shenzhen 518172,China;Department of Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;Sarcoma Multidisciplinary Program,Sylvester Comprehensive Cancer Center,The University of Miami,Miami,FL 33136,USA
Effect of vocal respiratory training on respiratory function and respiratory neural plasticity in patients with cervical spinal cord injury: a randomized controlled trial
Xiao-Ying Zhang-School of Rehabilitation Medicine,Capital Medical University,Beijing,China;China Rehabilitation Science Institute,Beijing,China;Beijing Key Laboratory of Neural Injury and Rehabilitation,Beijing,China;Center of Neural Injury and Repair,Beijing Institute for Brain Disorders,Beijing,China;Music Therapy Center,Department of Psychology,China Rehabilitation Research Center,Beijing,China;Department of Imaging,China Rehabilitation Research Center,Beijing,China;Department of Spinal and Neural Functional Reconstruction,China Rehabilitation Research Center,Beijing,China;Department of Music Artificial Intelligence and Music Scientific Technology,Central Conservatory of Music,Beijing,China
Effects of paired associative magnetic stimulation between nerve root and cortex on motor function of lower limbs after spinal cord injury: study protocol for a randomized controlled trial
Ting-Ting Sun;Guang-Yue Zhu;Ya Zheng;Ye-Ran Mao;Qi-Long Hu;Gong-Ming Song;Rong Xu;Qi Yang;Dan Zhao;Xu-Yun Hua;Dong-Sheng Xu-Shanghai Yangzhi Rehabilitation Hospital(Shanghai Sunshine Rehabilitation Center),School of Medicine,Tongji University,Shanghai,China;Rehabilitation Medical Center,TongjiHospital Affiliated to Tongji University School of Medicine,Shanghai,China;School of Rehabilitation Science,Shanghai University of Traditional Chinese Medicine,Shanghai,China;Engineering Research Center of Traditional Chinese Medicine Intelligent Rehabilitation,Ministry of Education,Shanghai,China;Department of Traumatology and Orthopedics,Yueyang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,China;Department of Rehabilitation Medicine,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai,China
Using a consensus acupoints regimen to explore the relationship between acupuncture sensation and lumbar spinal postoperative analgesia:A retrospective analysis of prospective clinical cooperation
Yen-Lin Chao;Yi-Ai Rau;Hong-Sheng Shiue;Jiun-Lin Yan;Yuan-Yun Tang;Shao-Wen Yu;Bo-Yan Yeh;Yen-Lung Chen;Tsung-Hsien Yang;Shu-Chen Cheng;Yi-Wen Hsieh;Hsin-Chia Huang;Fu-Kuang Tsai;Yu-Sheng Chen;Geng-Hao Liu-Division of Acupuncture and Moxibustion,Department of Traditional Chinese Medicine,Chang Gung Memorial Hospital,Taoyuan 333,Taiwan,China;School of Traditional Chinese Medicine,College of Medicine,Chang Gung University,Taoyuan 333,Taiwan,China;Department of Neurosurgery,Keelung Chang Gung Memorial Hospital,Keelung 204,Taiwan,China;Department of Traditional Chinese Medicine,New Taipei Municipal TuCheng Hospital,Chang Gung Memorial Hospital,New Taipei 236,Taiwan,China;Sleep Center,Chang Gung Memorial Hospital,Taoyuan 333,Taiwan,China
Dynamic changes of renal cortical blood perfusion before and after percutaneous transluminal renal artery stenting in patients with severe atherosclerotic renal artery stenosis
Ma Na;Li Yan;Wang Siyu;Li Mengpu;Li Yongjun;Ai Hu;Zhu Hui;Wang Yang;Guo Fajin;Ren Junhong-Department of Sonography, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Vascular Surgery, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Cardiology, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Nuclear Medicine, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Medical Research & Biometrics Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing 100037, China
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study
Sun Juxian;Liu Chang;Shi Jie;Wang Nanya;Jiang Dafeng;Mao Feifei;Gu Jingwen;Zhou Liping;Shen Li;Yee Lau Wan;Cheng Shuqun-Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Integrative Oncology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Outpatient Department, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Oncology, First Hospital of Jilin University, Changchun, Jilin 130000, China;Department of Oncology Zhejiang Sian International Hospital, Jiaxing, Zhejiang 314000, China;Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200040, China;Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR 999077, China
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。